68 results
8-K
EX-99.1
IMNN
Imunon Inc
1 Mar 06
Celsion Announces 1-FOR-15 Reverse Stock Split
12:00am
doxorubicin drug, ThermoDoxTM, including starting human clinical studies in two cancer indications and the recruitment of an experienced drug
8-K
EX-99.1
IMNN
Imunon Inc
16 Nov 20
Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update
8:46am
cancer.
“The OVATION 2 Study with our GEN-1 immunotherapy continues recruitment into the 100 mg/m² dose cohort,” said Michael H. Tardugno, Celsion’s … approximately five months ahead of our previously announced schedule. We have a very aggressive recruitment program in place and anticipate completing enrollment
8-K
EX-99.1
IMNN
Imunon Inc
14 Aug 20
Celsion Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update
8:22am
approximately five months ahead of our previously announced schedule. We have a very aggressive recruitment program and anticipate completing enrollment
8-K
EX-99.1
0wp966 y6aph96q27
16 May 07
Other Events
12:00am
8-K
44ot8xul1 kw2njlho
26 Feb 13
Entry into a Material Definitive Agreement
12:00am
424B5
1e4pj86
21 Jan 14
Prospectus supplement for primary offering
12:00am